The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia

Eric M. Mortensen, Marcos I. Restrepo, Antonio Anzueto, Jacqueline Pugh

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Recent studies suggest that angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of ACE inhibitors on mortality for patients hospitalized with community-acquired pneumonia. Methods: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation. Results: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk. In the multivariable conditional logistic regression analysis, after adjusting for potential confounders, the use of ACE inhibitors at presentation (odds ratio 0.44, 95% confidence interval 0.22-0.89) was significantly associated with 30-day mortality. Conclusion: Prior outpatient use of an ACE inhibitor was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.

Original languageEnglish (US)
Article number12
JournalBMC Pulmonary Medicine
Volume5
DOIs
StatePublished - Sep 13 2005

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Pneumonia
Outpatients
Mortality
International Classification of Diseases
Tertiary Care Centers
Teaching Hospitals
Cohort Studies
Thorax
Retrospective Studies
Logistic Models
Odds Ratio
Regression Analysis
X-Rays
Confidence Intervals
Infection
Research

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine

Cite this

The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia. / Mortensen, Eric M.; Restrepo, Marcos I.; Anzueto, Antonio; Pugh, Jacqueline.

In: BMC Pulmonary Medicine, Vol. 5, 12, 13.09.2005.

Research output: Contribution to journalArticle

@article{e1f0f90b15414451953d9ec089b62a97,
title = "The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia",
abstract = "Background: Recent studies suggest that angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of ACE inhibitors on mortality for patients hospitalized with community-acquired pneumonia. Methods: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were {"}comfort measures only{"} or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation. Results: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2{\%} at 30-days and 13.6{\%} at 90-days. At presentation 52{\%} of subjects were low risk, 34{\%} were moderate risk, and 14{\%} were high risk. In the multivariable conditional logistic regression analysis, after adjusting for potential confounders, the use of ACE inhibitors at presentation (odds ratio 0.44, 95{\%} confidence interval 0.22-0.89) was significantly associated with 30-day mortality. Conclusion: Prior outpatient use of an ACE inhibitor was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.",
author = "Mortensen, {Eric M.} and Restrepo, {Marcos I.} and Antonio Anzueto and Jacqueline Pugh",
year = "2005",
month = "9",
day = "13",
doi = "10.1186/1471-2466-5-12",
language = "English (US)",
volume = "5",
journal = "BMC Pulmonary Medicine",
issn = "1471-2466",
publisher = "BioMed Central",

}

TY - JOUR

T1 - The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia

AU - Mortensen, Eric M.

AU - Restrepo, Marcos I.

AU - Anzueto, Antonio

AU - Pugh, Jacqueline

PY - 2005/9/13

Y1 - 2005/9/13

N2 - Background: Recent studies suggest that angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of ACE inhibitors on mortality for patients hospitalized with community-acquired pneumonia. Methods: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation. Results: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk. In the multivariable conditional logistic regression analysis, after adjusting for potential confounders, the use of ACE inhibitors at presentation (odds ratio 0.44, 95% confidence interval 0.22-0.89) was significantly associated with 30-day mortality. Conclusion: Prior outpatient use of an ACE inhibitor was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.

AB - Background: Recent studies suggest that angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of ACE inhibitors on mortality for patients hospitalized with community-acquired pneumonia. Methods: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation. Results: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk. In the multivariable conditional logistic regression analysis, after adjusting for potential confounders, the use of ACE inhibitors at presentation (odds ratio 0.44, 95% confidence interval 0.22-0.89) was significantly associated with 30-day mortality. Conclusion: Prior outpatient use of an ACE inhibitor was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.

UR - http://www.scopus.com/inward/record.url?scp=26844485470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844485470&partnerID=8YFLogxK

U2 - 10.1186/1471-2466-5-12

DO - 10.1186/1471-2466-5-12

M3 - Article

C2 - 16159398

AN - SCOPUS:26844485470

VL - 5

JO - BMC Pulmonary Medicine

JF - BMC Pulmonary Medicine

SN - 1471-2466

M1 - 12

ER -